Use of steroids in neuro-oncology

被引:1
作者
Barbero-Bordallo, Natalia [1 ,2 ,3 ]
Gomez-Vicente, Lidia [4 ]
机构
[1] Hosp Univ Rey Juan Carlos, Serv Neurol, Gladiolo S-N, E-28933 Mostoles, Madrid, Spain
[2] Hosp Infanta Elena, Madrid, Spain
[3] Hosp Gen Villalba, Madrid, Spain
[4] Hosp Univ Quironsalud Madrid, Serv Neurol, Madrid, Spain
关键词
Brain metastases; Brain tumours; Cerebral oedema; Corticosteroids; Dexamethasone; Glioblastoma; Neurooncology; DEXAMETHASONE TREATMENT; BRAIN METASTASES; CEREBRAL EDEMA; MANAGEMENT; CANCER; CORTICOSTEROIDS; EXPRESSION; MECHANISM; TOXICITY; THERAPY;
D O I
10.33588/rn.6809.2019083
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Corticosteroids are widely used in routine clinical practice in neuro-oncology. However, despite their widespread use, there is no established consensus on their indications, dosages and dosage schedule. This article reviews the mechanism of action of corticosteroids, their indications for use, side effects and the appropriate management, dosage and duration of therapy, as well as the role of new treatments currently being use to treat cerebral oedema. The most widely used corticosteroid in neuro-oncology is dexamethasone, probably due to its low mineralocorticoid effect and its long half-life. Its effect on cerebral oedema is fundamental in the symptomatic control of patients with brain tumours. It is recommended to start treatment only in symptomatic patients, in doses of 4-8 mg/24 h, always seeking the minimum effective dosage. Side effects associated with corticosteroid use are common and have a negative impact on patient's quality of life.
引用
收藏
页码:389 / 397
页数:9
相关论文
共 55 条
[1]   Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].
Arbour, Kathryn C. ;
Mezquita, Laura ;
Long, Niamh ;
Rizvi, Hira ;
Auclin, Edouard ;
Ni, Andy ;
Martinez-Bernal, Gala ;
Ferrara, Roberto ;
Lai, W. Victoria ;
Hendriks, Lizza E. L. ;
Sabari, Joshua K. ;
Caramella, Caroline ;
Plodkowski, Andrew J. ;
Halpenny, Darragh ;
Chaft, Jamie E. ;
Planchard, David ;
Riely, Gregory J. ;
Besse, Benjamin ;
Hellmann, Matthew D. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+
[2]   Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging [J].
Armitage, Paul A. ;
Schwindack, Chris ;
Bastin, Mark E. ;
Whittle, Ian R. .
MAGNETIC RESONANCE IMAGING, 2007, 25 (03) :303-310
[3]   Steroid myopathy in cancer patients [J].
Batchelor, TT ;
Taylor, LP ;
Thaler, HT ;
Posner, JB ;
DeAngelis, LM .
NEUROLOGY, 1997, 48 (05) :1234-1238
[4]  
CHAMBERLIN P, 1981, PEDIATRICS, V67, P245
[5]   Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids [J].
Czock, D ;
Keller, F ;
Rasche, FM ;
Häussler, U .
CLINICAL PHARMACOKINETICS, 2005, 44 (01) :61-98
[6]   The hiccup reflex arc and persistent hiccups with high-dose anabolic steroids: Is the brainstem the steroid-responsive locus? [J].
Dickerman, RD ;
Jaikumar, S .
CLINICAL NEUROPHARMACOLOGY, 2001, 24 (01) :62-64
[7]   STEROID-INDUCED WEAKNESS IN PATIENTS WITH PRIMARY BRAIN-TUMORS [J].
DROPCHO, EJ ;
SOONG, SJ .
NEUROLOGY, 1991, 41 (08) :1235-1239
[8]   Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia [J].
Einaudi, Silvia ;
Bertorello, Nicoletta ;
Masera, Nicoletta ;
Farinasso, Loredana ;
Barisone, Elena ;
Rizzari, Carmelo ;
Corrias, Andrea ;
Villa, Alessia ;
Riva, Francesca ;
Saracco, Paola ;
Pastore, Guido .
PEDIATRIC BLOOD & CANCER, 2008, 50 (03) :537-541
[9]   Assessment of Brain Tumor Response: RANO and Its Offspring [J].
Eisele, Sylvia C. ;
Wen, Patrick Y. ;
Lee, Eudocia Q. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (07)
[10]   Incidence and risk factors for corticosteroid-induced lipodystrophy: A prospective study [J].
Fardet, Laurence ;
Cabane, Jean ;
Lebbe, Celeste ;
Morel, Patrice ;
Flahault, Antoine .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (04) :604-609